Summary
Despite the enormous benefits provided by antipsychotic medication in the management of schizophrenia, available compounds have serious limitations. Firstly, they are not always effective. Secondly, positive psychopathological symptoms may benefit more than negative or deficit symptoms. Thirdly, antipsychotics are generally associated with a variety of neurological adverse effects.
Three drugs have recently been or are close to being introduced into widespread clinical use: clozapine, risperidone and remoxipride. Each of these compounds appears to have some advantages over traditional antipsychotic agents, particularly in terms of reduced propensity to induce adverse neurological effects. All three drugs have been shown to be clinically effective in large scale trials. Future clinical trials are required to establish their relative merits in comparison with one another.
Similar content being viewed by others
References
Bersani G, Bresa GM, Meco G, Marini S, Pozzi F. Combined serotonin-5HT2 and dopamine D-2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone. Human Psychopharmacology 5: 225–231, 1990
Bersani G, Grispini A, Marini S, Pasini A, Valducci M, et al. Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R55667), a new selective 5-HT2 receptor blocking agent. Current Therapeutic Research 40: 492–499, 1986
Borison R. Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. Presented at First International Risperidone Investigators Meeting. Paris, France, March 9–10, 1992
Chouinard G, Jones B, Remington G, Bloom D, Addington D, et al. A Canadian Multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology 13: 25–40, 1993
Christisen GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin 17: 217–246, 1991
Coward DM, Imperato A, Urwyler S, White TG. Biochemical and behavioral properties of clozapine. Psychopharmacology 99: S6–S12, 1989
Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 41: 369–371, 1991
Farde L, Wiesel SA, Nordstrom AL, Sedvall G. D-1 and D-2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99: 528–531, 1989
Gelders YG. Thymosthenic agents, a novel approach in the treatment of schizophrenia. British Journal of Psychiatry 155 (Suppl. 5): 33–36, 1989
Heinrich K, Klieser E, Lehmann E, Kinzler E. Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia. 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum, Kyoto, September 1990
Janssen PAJ, Niemegeers EJE, Awouters E, Schellekens KHL, Megens AAHP, et al. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. Journal of Pharmacology and Experimental Therapeutics 244: 685–693, 1988
Kane JM, Cooper TB, Sachor EJ, Halpern FS, Bailine S. Clozapine plasma levels and prolactin response. Psychopharmacology 73: 184–187, 1981
Kane J, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45: 789–796, 1988
Kane J. The efficacy of clozapine in the treatment of schizophrenia: a long term perspective. Journal of Clinical Psychiatry 8: 9–14, 1990
Kay SR, Fiszbin A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13: 261–276, 1987
King DJ, Blomqvist M, Cooper SJ, Doherty MM, Mitchell MJ, et al. A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia. Psychopharmacology 107: 175–179, 1992
Kohler C, Hall H, Magnusson O, Lewander T, Gustafsson K. Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 27–36, 1990
Lapierre YD, Nair NPV, Awad AG, Chouinard G, Saxena B, et al. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia — A Canadian multicentre trial. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 72–77, 1990
Lewander T, Westerbergh S-E, Morrison D. Clinical profile of remoxipride. A combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 92–98, 1990
Leysen JE, Janssen PMF, Gommeren W, Wynants J, Pauwels PJ, et al. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel anti-psychotics risperidone and ocaperidone. Molecular Pharmacology 41: 494–508, 1992
Lindstrom LH. The effect of long-term treatment of clozapine in schizophrenia: a retrospective study of 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica 77: 524–529, 1987
Lieberman J, Alvir J. A report of clozapine-induced agranulocytosis in the United States. Drug Safety (Suppl. 7): 1–2, 1992
Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, et al. The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry 158: 503–510, 1991
Lieberman JA, Yunis J, Egea E, Conoso RT, Kane JM, et al. HLA B38, DR4, DQW3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry 47: 945–948, 1990
Lopez-Ibor Alino JJ. Risperidone: Safety and side effect profile. Presentation at First International Risperidone Investigators Meeting. Paris, France. March 9–10, 1992
Marder SR. Risperidone: efficacy on positive and negative symptoms. Presentation at First International Risperidone Investigators Meeting. Paris, France. March 9–10, 1992a
Marder SR. Risperidone: clinical development: North American results. Clinical Neuropharmacology 15 (Suppl.): 92A–93A, 1992b
Mattes JA. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to two years. Journal of Clinical Psychiatry 50: 389–391, 1989
McElroy SL, Dessain EC, Pope HG, Cole JO, Keck PE, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder and schizophrenia. Journal of Clinical Psychiatry 52: 411–414, 1991
Meltzer HY. Dimensions of outcome with clozapine. British Journal of Psychiatry 160 (Suppl.): 46–53, 1992
Mertens C. Long-term experience with risperidone. Presentation at First International Risperidone Investigators Meeting. Paris, France. March 9–10, 1992
Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, et al. Therapeutic effect and safety of increasing doses of risperidone (R 64 766) in psychotic patients. Psychopharmacology 99: 445–449, 1989
Moller HJ. Incidence of EPS under risperidone therapy. Presentation at First International Risperidone Investigators Meeting. Paris, France. March 9–10, 1992
Morrison D, Englund A, Lawrie V, Lewander T, Schlachet A, et al. Safety evaluation in both short and long-term treatment of schizophrenia with remoxipride. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 164–169, 1990
Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects in the treatment of schizophrenia and tardive dyskinesia. A retrospective study of 387 patients. Psychopharmacology 99: S73–S76, 1989
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 10: 799–812, 1962
Owen RR, Beake BJ, Marby D, Dessain EC, Cole JO. Response to clozapine in chronic psychotic patients. Psychopharmacology Bulletin 25: 253–256, 1989
Patris M, Agussol P, Alby JM, Brion S, Burnat G, et al. A double-blind multicenter comparison of remoxipride, at two dose levels, and haloperidol. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 78–82, 1990
Pfeiffer RF, Kang J, Graber B, Hoffman R, Wilson J. Clozapine for psychosis in parkinson’s disease. Movement Disorders 5: 239–242, 1990
Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, et al. Clinical and biologic response to clozapine in patients with schizophrenia. Archives of General Psychiatry 49: 345–361, 1992
Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA. On the possible mechanisms and predictability of clozapine-induced agranulocytosis. Drug Safety 7 (Suppl. 1) 33–44, 1992
Richelson E. Pharmacology of neuroleptics in use in the United States. Journal of Clinical Psychiatry 46: 8–13, 1985
Schotte A, de Bruyckere K, Janssen PFM, Leysen JE. Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain Research 500: 295–301, 1989
Sokoloff P, Giros B, Martres MP, Bouthenet M-L, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151, 1990
Sunahara RK, Guan H-C, O’Dowd BF, Seaman P, Lawrier LG, et al. Cloning of the gene for human dopamine D5 receptor with higher affinity for dopamine than Dj. Nature 350: 614–616, 1991
Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biological Psychiatry 32: 270–280, 1992
Van-Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seaman P, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614, 1991
Wadworth AN, Heel RC. Remoxipride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in schizophrenia. Drugs 40: 863–879, 1990
Walinder J, Holm A-C. Experiences of long-term treatment with remoxipride: efficacy and tolerability. Acta Psychiatrica Scandinavica 82 (Suppl. 358): 158–163, 1990
Watling KJ, Beer MS, Newberry NR. Interaction of the atypical neuroleptic clozapine with five HT-3 receptors in the cerebral cortex and superior cervical ganglion of the rat. European Journal of Pharmacology 182: 465–472, 1991
Wolk SI, Douglas CJ. Clozapine treatment of psychosis in parkinson’s disease: a report of five consecutive cases. Journal of Clinical Psychiatry 53: 373–376, 1992
Wolters EC, Hurvitz TA, Peppard RF, Calne DB. Clozapine: an antipsychotic agent in parkinson’s disease? Clinical Neuropharmacology 12: 83–90, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kane, J.M. Newer Antipsychotic Drugs. Drugs 46, 585–593 (1993). https://doi.org/10.2165/00003495-199346040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199346040-00002